Morgan Stanley Reaffirms Buy on Intuitive Surgical With $650 Target, Pointing to Endoluminal Robotics Upside
Fresh PARADIGM results on complex colorectal ESD are cited as evidence that endoluminal procedures could widen the role of robotics.
Overview
- On September 29, Morgan Stanley’s Patrick Wood maintained a Buy rating on Intuitive Surgical and set a $650 price target.
- The call highlights potential in endoluminal robotics following EndoQuest’s PARADIGM trial showing feasibility of ESD for complex colorectal lesions.
- Wood notes ESD is technically demanding yet may deliver better clinical outcomes than common U.S. approaches, which could accelerate robotic adoption.
- Intuitive’s portfolio, including the Ion Endoluminal platform and Da Vinci surgical systems, underpins the investment thesis cited in the report.
- The rating and rationale were reported by Insider Monkey and republished by Yahoo Finance, reflecting continued analyst optimism on ISRG.